Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methotrexate subcutaneous auto-injection - Assertio Therapeutics

Next Previous
X
Search
Drug Profile

Methotrexate subcutaneous auto-injection - Assertio Therapeutics

Alternative Names: Otrexup; VIBEX MTX

Latest Information Update: 26 May 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Antares Pharma
  • Class Abortifacients; Anti-inflammatories; Antiasthmatics; Antifibrotics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Disease-modifying antirheumatics; Eye disorder therapies; Glutamates; Heart failure therapies; Pterins; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Female genital diseases
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Juvenile rheumatoid arthritis; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 24 May 2022 Antares Pharma has been acquired by Halozyme Therapeutics
  • 15 Dec 2021 Assertio Therpeutics acquires Methotrexate subcutaneous auto-injection from Antares Pharma in December 2021
  • 28 Mar 2019 Methotrexate subcutaneous auto-injection receives Orphan Drug status for Female genital diseases (Ectopic pregnancy) in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top